Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03396445 |
| Title | Safety and Pharmacokinetics Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Merck Sharp & Dohme Corp |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | NLD | ISR | ESP |